<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Encapsulating peritoneal sclerosis in patients on peritoneal dialysis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Encapsulating peritoneal sclerosis in patients on peritoneal dialysis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Encapsulating peritoneal sclerosis in patients on peritoneal dialysis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John M Burkart, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shweta Bansal, MD, FASN</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3199182547"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Encapsulating peritoneal sclerosis (EPS) is a rare complication of peritoneal dialysis that is characterized by intraperitoneal inflammation and fibrosis, which at times results in the encasement of bowel loops. EPS causes ultrafiltration failure and bowel obstruction and is associated with significant morbidity and a high mortality.</p><p>This topic reviews EPS. Other, more common complications related to peritoneal dialysis are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1869.html" rel="external">"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1973.html" rel="external">"Inadequate solute clearance in peritoneal dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1888.html" rel="external">"Peritoneal catheter exit-site and tunnel infections in peritoneal dialysis in adults"</a>.)</p><p></p><p>Factors that regulate solute and water transport across the peritoneal membrane are discussed separately. (See  <a class="medical medical_review" href="/d/html/1878.html" rel="external">"Mechanisms of solute clearance and ultrafiltration in peritoneal dialysis"</a>.)</p><p class="headingAnchor" id="H2794238622"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of EPS is not well understood [<a href="#rid1">1</a>]. EPS is believed to be a result of inflammation in the peritoneum, which causes progressive peritoneal mesothelial cell loss, submesothelial fibrosis, and peritoneal capillary angiogenesis [<a href="#rid2">2</a>]. The inflammation is presumed to be due to the dialysis procedure itself and may be related to exposure to glucose or glucose degradation products and advanced glycosylation end products in peritoneal dialysis fluids. It has been proposed that by increasing the cytosolic NADH to NAD<sup>+</sup> ratio, high glucose levels upregulate hypoxia-inducible factor 1, which stimulates a variety of proinflammatory and profibrotic pathways [<a href="#rid3">3</a>].</p><p>An increase in fibrinogenesis and in endothelial permeability causes exuberant fibrin deposition on the peritoneum [<a href="#rid4">4</a>]. Any process that increases inflammation, such as episodes of bacterial peritonitis, may cause increases in permeability and fibrin deposition [<a href="#rid5">5</a>].</p><p>Some have speculated that increased activity of the local renin-angiotensin system (RAS) in mesothelial cells may contribute to fibrin accumulation. Observational cohort data suggest that patients treated with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) (which inhibit the RAS) are less likely to have functional changes consistent with peritoneal fibrosis [<a href="#rid6">6,7</a>].</p><p>Repeated fibrin deposition causes formation of a dense capsule surrounding the small bowel, which may cause obstruction. Capsule formation and risk for adhesions and bowel encapsulation may be accelerated after peritoneal dialysis is discontinued. This is because fluid exchanges that are performed during peritoneal dialysis tend to wash away some of the excessive fibrin. When peritoneal dialysis is stopped, the inflammatory reaction and fibrin production continue, but fibrin is no longer washed away by peritoneal dialysis exchanges [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H2234350355"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>EPS is rare. Among patients on peritoneal dialysis, the reported incidence varies between 0.7 and 13.6 per 1000 patient-years [<a href="#rid8">8-14</a>]. Limitations in study design and detection bias likely contribute to variability in reported individual risk. Many patients with EPS present after peritoneal dialysis has been discontinued (usually for repeated peritonitis episodes, ultrafiltration failure, or because patients receive kidney transplants); these patients are often not included in studies. There is no good screening test, which means that many patients with mild or early cases of EPS are not diagnosed. In addition, some patients who have mild peritoneal fibrosis may be misdiagnosed as having EPS. Not all instances of mild peritoneal fibrosis are true cases of EPS. Also, most studies do not account for competing risks of death. In a study of more than 17,000 patients on peritoneal dialysis, the estimated risk of EPS after five years fell by more than half when the competing risk of death was taken into account [<a href="#rid15">15</a>].</p><p>The risk also varies among centers and countries. This variability has been attributed to many factors such as genetic differences and differences in peritoneal dialysis protocols (prescribed volumes, peritoneal dialysis glucose concentration, use of biocompatible fluids, and time spent on peritoneal dialysis) [<a href="#rid8">8</a>].</p><p>The risk of EPS may be higher among transplant recipients who used to be on peritoneal dialysis compared with patients who are still on peritoneal dialysis and have not received a transplant [<a href="#rid10">10,12-14</a>]. In one retrospective study that identified 18 patients with EPS, 15 had a history of kidney transplantation [<a href="#rid12">12</a>].</p><p>The reasons for the transplantation-associated risk are not known. The increased risk may be related to the cessation of dialysis itself since, once the inflammation process has started, peritoneal lavage with peritoneal dialysis may limit fibrin accumulation and be protective. In addition, calcineurin inhibitors, which are a commonly used antirejection medication, are profibrotic and thus may worsen fibrin deposition. (See  <a class="medical medical_review" href="/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Side effects'</a>.)</p><p>However, among patients who have EPS, transplantation may increase survival, and EPS is not a contraindication to transplantation. (See <a class="local">'Prognosis'</a> below.)</p><p>EPS has been reported among patients not on peritoneal dialysis, but this entity is vanishingly rare [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H2920506627"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>The two major risk factors for EPS are duration of time on peritoneal dialysis and severe, recurrent peritonitis. There are multiple other suggested risk factors.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Time on peritoneal dialysis</strong> – The duration of time on peritoneal dialysis is the major risk factor for EPS [<a href="#rid8">8-11,17-20</a>]. In a prospective, multicenter study from 57 facilities in Japan, among a total of 1958 patients, the incidence of EPS was 0, 0.7, 2.1, 5.9, 5.8, and 17.2 percent for those who had undergone peritoneal dialysis for 3, 5, 8, 10, 15, and greater than 15 years, respectively [<a href="#rid9">9</a>]. Similar findings have been found in other studies as well [<a href="#rid10">10,11,17,18</a>]. In one Australian and New Zealand survey, the incidence of EPS was 0.3, 0.8, and 3.9 percent for patients on peritoneal dialysis for three, five, and eight years, respectively [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe peritonitis</strong> – Multiple episodes of severe peritonitis (particularly with <em>Staphylococcus aureus</em> species, fungus, and <em>Pseudomonas</em>) are a risk factor [<a href="#rid10">10-14,21</a>]. In a study of 100 patients with EPS, 28 patients had one previous episode of peritonitis, 29 had two previous episodes, and 33 had three or more [<a href="#rid21">21</a>]. Only 10 patients did not have a history of peritonitis.</p><p></p><p class="bulletIndent1">Repeated episodes of mild peritonitis do not appear to be a risk factor for EPS [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific dialysate fluids </strong>– Higher dialysate glucose concentration, the use of acetate as a dialysate buffer, and bioincompatible dialysate may be risk factors. We do not believe there are sufficient data to suggest that <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a> is a risk factor. (See  <a class="medical medical_review" href="/d/html/1905.html" rel="external">"Peritoneal dialysis solutions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific drugs </strong>– Beta blockers and calcineurin inhibitors may be risk factors [<a href="#rid10">10-14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decreased ultrafiltration and increased solute transport </strong>– A disproportionate decrease in ultrafiltration capacity compared with decline in solute transport (ie, uncoupling) may identify increased EPS risk [<a href="#rid1">1</a>]. In addition, decreased free-water transport alone and in combination with biomarkers may help predict EPS [<a href="#rid22">22</a>]. Larger studies are required to confirm these observations before they are introduced in routine clinical practice.</p><p></p><p>The utility of biomarkers in identifying patients at risk for EPS is unclear [<a href="#rid1">1,8,22</a>]. Inflammatory cytokines including interleukin (IL) 6, tumor necrosis factor (TNF)-alpha, monocyte chemoattractant protein 1 (MCP-1), plasminogen activator inhibitor type 1, and others are mildly increased and cancer antigen 125 is decreased in patients who go on to develop clinical signs of EPS. However, there is marked variability in biomarker concentrations, and their predictive ability has not been demonstrated. Thus, they are not routinely checked in clinical practice.</p><p class="headingAnchor" id="H3962203153"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Reliable preventive measures have not been identified. Among all patients on peritoneal dialysis, possible preventive strategies include limiting use of high-glucose dialysate as much as possible and using biocompatible, or "neutral," peritoneal dialysis fluids. (See  <a class="medical medical_review" href="/d/html/1905.html" rel="external">"Peritoneal dialysis solutions"</a>.)</p><p>Since the major risk factor is the duration of time on peritoneal dialysis (particularly after five or more years), some have advocated a time limit for peritoneal dialysis (see <a class="local">'Risk factors'</a> above). However, we do not set a time limit for peritoneal dialysis, since the vast majority of patients on peritoneal dialysis do not develop EPS, and the potential benefit of preemptively stopping peritoneal dialysis is offset by the risks associated with hemodialysis [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/1881.html" rel="external">"Acute complications during hemodialysis"</a>.)</p><p>In addition, studies suggest that patients who may have already started to develop the inflammatory process (but which may not be clinically evident yet) worsen <strong>after </strong>peritoneal dialysis is discontinued [<a href="#rid10">10</a>].</p><p>Some clinicians rest the peritoneal membrane (ie, stop peritoneal dialysis and perform hemodialysis for a number of weeks to months) among patients who have one or more risk factors, such as those who have repeated episodes of severe peritonitis or who show decreases in ultrafiltration or increased solute transport. However, this practice is controversial since EPS may present or worsen after peritoneal dialysis is stopped [<a href="#rid10">10</a>]. If the decision is made to rest the membrane, then a short peritoneal dialysis dwell or lavage should be performed twice weekly just to flush the membrane and minimize possible adhesion formation. (See <a class="local">'Treatment'</a> below.)</p><p class="headingAnchor" id="H2041160361"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H2363625916"><span class="h2">History and physical</span><span class="headingEndMark"> — </span>EPS is a slowly progressive, frequently asymptomatic disorder that occurs after many years on peritoneal dialysis (generally &gt;5 years), often complicated by multiple episodes of severe peritonitis.</p><p>EPS develops in a stepwise fashion, and early (inflammatory) and late (ileus) stages have been identified.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early </strong>– Early signs and symptoms described by the patient are nonspecific and include anorexia, nausea, diarrhea, and intermittent abdominal pain.</p><p></p><p class="bulletIndent1">The physical exam is often unrevealing in early stages, although, among patients who are still on peritoneal dialysis, blood-tinged dialysate/ascites may be observed on exchanges, especially after periods where the peritoneal dialysis cavity has been dry [<a href="#rid1">1</a>]. Patients who are still on peritoneal dialysis may develop progressive volume overload and lower ultrafiltration volumes, despite adjusting the peritoneal dialysis prescription to increase ultrafiltration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late </strong>–<strong> </strong>More prominent clinical features occur in the late stage and result from ileus and/or peritoneal adhesions [<a href="#rid23">23</a>]. With encapsulation of the bowel, the patient develops symptoms of intermittent obstruction including severe cramping, abdominal pain, constipation, and vomiting. In a study of 111 patients with severe, late-stage EPS, the most commonly reported symptoms were abdominal pain and vomiting in 67 and 59 percent of patients, respectively [<a href="#rid21">21</a>]. By this stage, the exam may reveal an abdominal mass. Occasionally, bowel symptoms may occur in the absence of ultrafiltration failure (although careful review of the chart may show that the patient may have had the prescription adjusted to increase ultrafiltration).</p><p></p><p>At times after discontinuation of peritoneal dialysis (such as posttransplant), a patient is diagnosed with ascites but has no symptoms of an ileus or obstruction [<a href="#rid21">21,24</a>]. This may be a sign of early EPS. Such patients may be less likely to develop bowel adhesions because the ascetic fluid keeps the bowel walls from becoming adherent.</p><p class="headingAnchor" id="H2479407024"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>There are no routine laboratory findings that suggest EPS. The peritoneal dialysis fluid may show white blood cells (WBCs), but these are low in number and are generally nonspecific. Serial peritoneal equilibration tests may show a trend toward increased solute transport and decreased ultrafiltration, specifically with low free-water transport rates [<a href="#rid25">25-27</a>], probably due to interference of interstitial collagen-1 with the crystalloid osmotic gradient, rather than due to a vasculopathy [<a href="#rid28">28</a>]. However, these changes are not observed in all patients with EPS and are commonly observed in the absence of EPS, particularly among patients who have been on peritoneal dialysis for a number of years.</p><p class="headingAnchor" id="H511497693"><span class="h2">Radiographic findings</span><span class="headingEndMark"> — </span>Computed tomography (CT) scan shows peritoneal calcification, bowel thickening, tethering, and dilatation [<a href="#rid4">4,8,29</a>]. Bowel tethering and peritoneal calcification are the most specific findings, although there are no radiographic abnormalities that are diagnostic in the absence of characteristic signs and symptoms [<a href="#rid29">29</a>]. A completely normal CT is unusual in late-stage disease but does not exclude early EPS.</p><p class="headingAnchor" id="H3480935785"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis is suspected in a patient who has been on peritoneal dialysis and who develops nonspecific gastrointestinal symptoms (such as abdominal pain, nausea, loss of appetite, constipation, diarrhea, vomiting) without obvious explanation, particularly in the setting of a progressive loss of ultrafiltration, resulting in fluid retention and edema.</p><p>A clue to the diagnosis may be found in the dialysis history. Sequential peritoneal equilibration testing (which is routinely performed to characterize membrane transport) may have demonstrated an initial increase from baseline in peritoneal solute transport followed by a decrease in solute transport [<a href="#rid8">8,23</a>]. The increase in peritoneal transport is often observed prior to onset of any gastrointestinal symptoms. (See  <a class="medical medical_review" href="/d/html/1972.html" rel="external">"Peritoneal equilibration test"</a> and  <a class="medical medical_review" href="/d/html/1914.html" rel="external">"Management of hypervolemia in patients on peritoneal dialysis", section on 'Peritoneal equilibration test'</a>.)</p><p>A presumptive diagnosis is generally made on the basis of clinical presentation and characteristic imaging (computed tomography [CT]) [<a href="#rid8">8,30</a>]. (See <a class="local">'Radiographic findings'</a> above.)</p><p>True confirmation of the diagnosis can only be made by laparotomy and/or laparoscopy, which demonstrates characteristic peritoneal thickening that encloses intestinal contents. However, laparotomy and/or laparoscopy are rarely done since they are invasive and associated with increased risk [<a href="#rid30">30</a>].</p><p>CT scanning is the key imaging technique for the diagnosis [<a href="#rid8">8</a>], although there are no radiographic abnormalities that are diagnostic in the absence of characteristic signs and symptoms [<a href="#rid29">29</a>]. (See <a class="local">'Radiographic findings'</a> above.)</p><p class="headingAnchor" id="H1850518607"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis for EPS is broad and depends on the specific presentation. The differential for later stages of EPS include all causes of intermittent obstruction, particularly malignancy.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8037.html" rel="external">"Etiologies, clinical manifestations, and diagnosis of mechanical small bowel obstruction in adults", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6862.html" rel="external">"Evaluation of the adult with abdominal pain", section on 'Diagnostic approach to chronic abdominal pain'</a>.)</p><p></p><p>EPS should not be confused with the generally benign and subclinical peritoneal fibrosis that occurs in most patients on peritoneal dialysis. The latter condition is characterized by increased fibrous tissue, predominantly in the parietal peritoneum (discerned by biopsy) [<a href="#rid31">31</a>], and is without symptoms or radiographic changes and almost always without evidence of failure of ultrafiltration [<a href="#rid32">32</a>]. The peritoneal fibrosis in this setting may be induced by episodes of peritonitis (particularly if severe) or may simply be a consequence of a prolonged duration of peritoneal dialysis.</p><p>Changes in ultrafiltration and solute transport are neither specific nor sensitive for EPS. Such changes commonly occur in patients without EPS, and patients with EPS may present without them. (See <a class="local">'History and physical'</a> above.)</p><p class="headingAnchor" id="H2208450938"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatment primarily consists of medical therapy with <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> and occasionally resting the peritoneum with a temporary switch to hemodialysis. Some patients require the cessation of peritoneal dialysis with a permanent switch to hemodialysis. All patients require close attention to nutritional status with supportive care as needed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tamoxifen</strong><strong> </strong>– We treat patients with <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>. We give 10 mg three times daily for at least three months. We also give <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 40 mg daily for at least four months followed by a prednisone taper over an additional six to eight weeks [<a href="#rid9">9,33-36</a>].</p><p></p><p class="bulletIndent1">In a number of case series and retrospective analyses, <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> was associated with better survival [<a href="#rid24">24,37,38</a>]. In a retrospective analysis of a registry including 63 patients diagnosed with severe EPS between 1996 and 2007, tamoxifen was associated with lower mortality (46 versus 74 percent in patients not treated with tamoxifen) [<a href="#rid24">24</a>]. However, one study showed no difference in outcome between patients treated with tamoxifen versus those who were not [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1">Well-studied side effects of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> include venous thromboembolic events and increased risk of endometrial cancer and uterine malignancy. There are little data on side effects among patients with EPS. One report of four EPS patients treated with tamoxifen described two episodes of clotted hemodialysis access and a nonfatal pulmonary embolism [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/764.html" rel="external">"Managing the side effects of tamoxifen and aromatase inhibitors", section on 'Venous thromboembolism'</a> and  <a class="medical medical_review" href="/d/html/764.html" rel="external">"Managing the side effects of tamoxifen and aromatase inhibitors", section on 'Uterine bleeding, hyperplasia, and cancer'</a>.)</p><p></p><p class="bulletIndent1">The additional benefit, if any, that is provided by <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is not clear [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resting the peritoneum </strong>– We rest the peritoneum in selected patients. This is based on our collective experience that resting the peritoneum may alleviate symptoms. Such patients must be maintained on hemodialysis via a temporary central venous catheter [<a href="#rid40">40,41</a>].</p><p></p><p class="bulletIndent1">The selection of patients cannot be based on any laboratory parameter but rather on clinical judgment and depending on severity of symptoms and on the burden placed by hemodialysis. If peritoneal dialysis is stopped, the peritoneum should be flushed twice weekly to minimize adhesions. We typically instill 100 to 200 mL of 1.36 percent dialysate containing 3500 international units of heparin (which is allowed to dwell for 30 minutes and then drained) [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1">The duration of the rest is typically 4 to 12 weeks, depending on symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stopping peritoneal dialysis </strong>– We do not permanently stop peritoneal dialysis in all patients. The decision to stop peritoneal dialysis must be individualized and is only made after careful consideration of the risks and benefits of peritoneal dialysis versus hemodialysis. For some patients, the gastrointestinal symptoms associated with early EPS may be preferred to the complications of hemodialysis (including infectious and noninfectious complications of the hemodialysis access) as well as the lifestyle changes associated with initiating hemodialysis. (See  <a class="medical medical_review" href="/d/html/1844.html" rel="external">"Dialysis modality and patient outcome", section on 'Selection of dialysis modality'</a>.)</p><p></p><p class="bulletIndent1">In addition, as noted above, the signs and symptoms of EPS such as small bowel obstruction and abdominal discomfort may <strong>worsen</strong> after stopping peritoneal dialysis, and there are no reliable indicators of which patients will worsen. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1">If the decision is made to stop peritoneal dialysis, we remove the peritoneal dialysis catheter and place a tunneled catheter for hemodialysis. Some clinicians advocate keeping the peritoneal dialysis catheter in place and using it to lavage the peritoneum; however, there are no data to support this approach.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care </strong>– Patients should be closely followed for evidence of developing malnutrition. We do not use total <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> unless patients do not tolerate oral intake or have evidence of developing malnutrition. (See  <a class="medical medical_review" href="/d/html/1856.html" rel="external">"Pathogenesis and treatment of malnutrition in patients on maintenance hemodialysis", section on 'Diagnosis of PEW'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical interventions </strong>– Patients with EPS are at risk for acute obstruction due to adhesions. The acute management of such patients is similar to other patients with mechanical small bowel obstruction. (See  <a class="medical medical_review" href="/d/html/89300.html" rel="external">"Management of small bowel obstruction in adults"</a>.)</p><p></p><p class="bulletIndent1">Surgery for relief of chronic symptoms is not commonly performed, because of the risk for worsening adhesions and unrecognized perforations [<a href="#rid30">30,42</a>]. Two reports have been published from one center that described a benefit of total enterolysis in EPS patients with severe anorexia and weight loss [<a href="#rid9">9,43</a>]. In a retrospective study of 50 patients with EPS who underwent enterolysis, 46 patients (94 percent) had complete relief from bowel obstructive symptoms, with an average follow-up period of 35 months [<a href="#rid43">43</a>]. Two patients died, and two continued to have mild subacute symptoms.</p><p></p><p class="bulletIndent1">Surgery for treatment of chronic symptoms should only be considered in a center with experience in the care of patients with EPS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other therapies </strong>– A variety of immunosuppressive agents have been used to treat EPS, either alone or in combination with glucocorticoids. These agents include <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, mammalian target of rapamycin (mTOR) inhibitors such as <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>, and <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> [<a href="#rid44">44</a>]. However, the evidence to support the use of these medications for the treatment of EPS is limited to case reports.</p><p></p><p class="headingAnchor" id="H1804502727"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Historically, the reported mortality associated with EPS was very high, ranging from 35 to 50 percent in some series [<a href="#rid8">8,9,30,42</a>]. In an analysis of data from a Dutch registry of 53 cases from 2009 to 2015, the one- and two-year survival were 67 and 52 percent, respectively [<a href="#rid37">37</a>].</p><p>Transplantation may confer a survival benefit among those who have EPS. Two retrospective studies have suggested an association of transplantation with better survival among patients with EPS [<a href="#rid21">21,24</a>]. Supportive care (nutritional supplementation), treatment with <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>, and use of glucocorticoids may have contributed to the improved survival.</p><p class="headingAnchor" id="H2953661833"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a>.)</p><p class="headingAnchor" id="H772362276"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Encapsulating peritoneal sclerosis (EPS) is a rare complication of peritoneal dialysis that is characterized by intraperitoneal inflammation and fibrosis and results in the encasement of bowel loops. (See <a class="local">'Introduction'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – The major risk factors for EPS are duration of time on peritoneal dialysis and episodes of severe peritonitis. Other possible risk factors include higher dialysate glucose concentration, the use of acetate as a dialysate buffer, the use of drugs such as beta blockers, and transplantation. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Possible preventive strategies include limiting use of high-glucose dialysate and using biocompatible, or "neutral," peritoneal dialysis fluids. We do not set a time limit for peritoneal dialysis, since most patients on peritoneal dialysis do not develop EPS, and the potential benefit of stopping peritoneal dialysis is offset by the risks associated with hemodialysis. EPS may also worsen when peritoneal dialysis is stopped. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Early signs and symptoms include anorexia, nausea, diarrhea, and intermittent abdominal pain. With encapsulation of the bowel, the patient develops severe cramping, abdominal pain, constipation, and vomiting due to obstruction. In later stages, the exam may reveal an abdominal mass. There are no routine laboratory findings that suggest EPS. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis is usually made on the basis of presentation and computed tomography (CT) imaging. A suggestive clinical history includes gastrointestinal symptoms without obvious cause, particularly in the setting of progressive ultrafiltration failure resulting in fluid overload. Sequential peritoneal equilibration testing that shows an increase followed by a decrease in solute transport prior to the onset of gastrointestinal symptoms strongly supports the diagnosis but is not a specific nor sensitive finding. True confirmation of the diagnosis can only be made by laparotomy and/or laparoscopy, but these are rarely done. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – For most patients on peritoneal dialysis with EPS, we suggest treatment with <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). A preferred regimen is daily tamoxifen (10 mg three times daily) for at least three months, with prednisone (40 mg daily) for at least four months, followed by a prednisone taper over an additional six to eight weeks. The decision to stop peritoneal dialysis must be individualized and is only made after careful consideration of the risks and benefits of peritoneal dialysis versus hemodialysis. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The reported mortality associated with EPS is very high. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Brown EA, Bargman J, van Biesen W, et al. Length of Time on Peritoneal Dialysis and Encapsulating Peritoneal Sclerosis - Position Paper for ISPD: 2017 Update. Perit Dial Int 2017; 37:362.</a></li><li><a class="nounderline abstract_t">Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12:14.</a></li><li><a class="nounderline abstract_t">Krediet RT, Parikova A. Relative Contributions of Pseudohypoxia and Inflammation to Peritoneal Alterations with Long-Term Peritoneal Dialysis Patients. Clin J Am Soc Nephrol 2022; 17:1259.</a></li><li><a class="nounderline abstract_t">Kawanishi H, Shintaku S, Banshodani M, Hashimoto S. Past and present perspectives on encapsulating peritoneal sclerosis. Contrib Nephrol 2015; 185:87.</a></li><li><a class="nounderline abstract_t">Kawanishi H, Harada Y, Noriyuki T, et al. Treatment options for encapsulating peritoneal sclerosis based on progressive stage. Adv Perit Dial 2001; 17:200.</a></li><li><a class="nounderline abstract_t">Kolesnyk I, Dekker FW, Noordzij M, et al. Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients. Perit Dial Int 2007; 27:446.</a></li><li><a class="nounderline abstract_t">Kolesnyk I, Noordzij M, Dekker FW, et al. A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant 2009; 24:272.</a></li><li><a class="nounderline abstract_t">Brown EA, Van Biesen W, Finkelstein FO, et al. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD. Perit Dial Int 2009; 29:595.</a></li><li><a class="nounderline abstract_t">Kawanishi H, Kawaguchi Y, Fukui H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004; 44:729.</a></li><li><a class="nounderline abstract_t">Brown MC, Simpson K, Kerssens JJ, et al. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol 2009; 4:1222.</a></li><li><a class="nounderline abstract_t">Johnson DW, Cho Y, Livingston BE, et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int 2010; 77:904.</a></li><li><a class="nounderline abstract_t">Korte MR, Yo M, Betjes MG, et al. Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. Nephrol Dial Transplant 2007; 22:2412.</a></li><li><a class="nounderline abstract_t">Fieren MW, Betjes MG, Korte MR, Boer WH. Posttransplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int 2007; 27:619.</a></li><li><a class="nounderline abstract_t">de Freitas DG, Augustine T, Brown EA, et al. Encapsulating peritoneal sclerosis following renal transplantation - the UK experience. Am J Transplant 2007; 7:163.</a></li><li><a class="nounderline abstract_t">Lambie M, Teece L, Johnson DW, et al. Estimating risk of encapsulating peritoneal sclerosis accounting for the competing risk of death. Nephrol Dial Transplant 2019; 34:1585.</a></li><li><a class="nounderline abstract_t">Ghisla S, Mayhew SG. Identification and properties of 8-hydroxyflavin--adenine dinucleotide in electron-transferring flavoprotein from Peptostreptococcus elsdenii. Eur J Biochem 1976; 63:373.</a></li><li><a class="nounderline abstract_t">Nomoto Y, Kawaguchi Y, Kubo H, et al. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis 1996; 28:420.</a></li><li><a class="nounderline abstract_t">Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998; 13:154.</a></li><li><a class="nounderline abstract_t">Vizzardi V, Sandrini M, Zecchini S, et al. Encapsulating peritoneal sclerosis in an Italian center: thirty year experience. J Nephrol 2016; 29:259.</a></li><li><a class="nounderline abstract_t">Nakao M, Yamamoto I, Maruyama Y, et al. Risk factors for encapsulating peritoneal sclerosis: Analysis of a 36-year experience in a University Hospital. Nephrology (Carlton) 2017; 22:907.</a></li><li><a class="nounderline abstract_t">Balasubramaniam G, Brown EA, Davenport A, et al. The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2009; 24:3209.</a></li><li><a class="nounderline abstract_t">Barreto DL, Sampimon DE, Struijk DG, Krediet RT. Early Detection of Imminent Encapsulating Peritoneal Sclerosis: Free Water Transport, Selected Effluent Proteins, or Both? Perit Dial Int 2019; 39:83.</a></li><li><a class="nounderline abstract_t">Nakamoto H. Encapsulating peritoneal sclerosis--a clinician's approach to diagnosis and medical treatment. Perit Dial Int 2005; 25 Suppl 4:S30.</a></li><li><a class="nounderline abstract_t">Korte MR, Fieren MW, Sampimon DE, et al. Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. Nephrol Dial Transplant 2011; 26:691.</a></li><li><a class="nounderline abstract_t">Morelle J, Sow A, Hautem N, et al. Interstitial Fibrosis Restricts Osmotic Water Transport in Encapsulating Peritoneal Sclerosis. J Am Soc Nephrol 2015; 26:2521.</a></li><li><a class="nounderline abstract_t">Mujais S, Nolph K, Gokal R, et al. Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20 Suppl 4:S5.</a></li><li><a class="nounderline abstract_t">Rippe B, Venturoli D. Simulations of osmotic ultrafiltration failure in CAPD using a serial three-pore membrane/fiber matrix model. Am J Physiol Renal Physiol 2007; 292:F1035.</a></li><li><a class="nounderline abstract_t">Krediet RT. Ultrafiltration Failure Is a Reflection of Peritoneal Alterations in Patients Treated With Peritoneal Dialysis. Front Physiol 2018; 9:1815.</a></li><li><a class="nounderline abstract_t">Tarzi RM, Lim A, Moser S, et al. Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis. Clin J Am Soc Nephrol 2008; 3:1702.</a></li><li><a class="nounderline abstract_t">Kawaguchi Y, Saito A, Kawanishi H, et al. Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int 2005; 25 Suppl 4:S83.</a></li><li><a class="nounderline abstract_t">Garosi G, Di Paolo N, Sacchi G, Gaggiotti E. Sclerosing peritonitis: a nosological entity. Perit Dial Int 2005; 25 Suppl 3:S110.</a></li><li><a class="nounderline abstract_t">Williams JD, Craig KJ, von Ruhland C, et al. The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int Suppl 2003; :S43.</a></li><li><a class="nounderline abstract_t">Junor BJ, McMillan MA. Immunosuppression in sclerosing peritonitis. Adv Perit Dial 1993; 9:187.</a></li><li><a class="nounderline abstract_t">Mori Y, Matsuo S, Sutoh H, et al. A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Am J Kidney Dis 1997; 30:275.</a></li><li><a class="nounderline abstract_t">Martins LS, Rodrigues AS, Cabrita AN, Guimaraes S. Sclerosing encapsulating peritonitis: a case successfully treated with immunosuppression. Perit Dial Int 1999; 19:478.</a></li><li><a class="nounderline abstract_t">Summers AM, Clancy MJ, Syed F, et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int 2005; 68:2381.</a></li><li><a class="nounderline abstract_t">Betjes MG, Habib SM, Boeschoten EW, et al. Significant Decreasing Incidence of Encapsulating Peritoneal Sclerosis in the Dutch Population of Peritoneal Dialysis Patients. Perit Dial Int 2017; 37:230.</a></li><li><a class="nounderline abstract_t">del Peso G, Bajo MA, Gil F, et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial 2003; 19:32.</a></li><li><a class="nounderline abstract_t">Eltoum MA, Wright S, Atchley J, Mason JC. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int 2006; 26:203.</a></li><li><a class="nounderline abstract_t">Selgas R, Bajo MA, Castro MJ, et al. Managing ultrafiltration failure by peritoneal resting. Perit Dial Int 2000; 20:595.</a></li><li><a class="nounderline abstract_t">Zhe XW, Tian XK, Cheng L, Wang T. Effects of peritoneal resting on peritoneal fluid transport kinetics. Perit Dial Int 2007; 27:575.</a></li><li><a class="nounderline abstract_t">Lee HY, Kim BS, Choi HY, et al. Sclerosing encapsulating peritonitis as a complication of long-term continuous ambulatory peritoneal dialysis in Korea. Nephrology (Carlton) 2003; 8 Suppl:S33.</a></li><li><a class="nounderline abstract_t">Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25 Suppl 4:S39.</a></li><li><a class="nounderline abstract_t">Jagirdar RM, Bozikas A, Zarogiannis SG, et al. Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options. Int J Mol Sci 2019; 20.</a></li></ol></div><div id="topicVersionRevision">Topic 114179 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28676507" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Length of Time on Peritoneal Dialysis and Encapsulating Peritoneal Sclerosis - Position Paper for ISPD: 2017 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1347465" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35168992" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Relative Contributions of Pseudohypoxia and Inflammation to Peritoneal Alterations with Long-Term Peritoneal Dialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26023018" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Past and present perspectives on encapsulating peritoneal sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11510276" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Treatment options for encapsulating peritoneal sclerosis based on progressive stage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17602154" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18676349" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19910558" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15384025" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19541815" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Encapsulating peritoneal sclerosis in the new millennium: a national cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20375981" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17395649" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17984419" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Posttransplant encapsulating peritoneal sclerosis: a worrying new trend?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Encapsulating peritoneal sclerosis following renal transplantation - the UK experience</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30820552" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Estimating risk of encapsulating peritoneal sclerosis accounting for the competing risk of death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4321" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Identification and properties of 8-hydroxyflavin--adenine dinucleotide in electron-transferring flavoprotein from Peptostreptococcus elsdenii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8804242" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9481732" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Sclerosing peritonitis: the experience in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26521254" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Encapsulating peritoneal sclerosis in an Italian center: thirty year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27556577" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Risk factors for encapsulating peritoneal sclerosis: Analysis of a 36-year experience in a University Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19211652" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30478138" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Early Detection of Imminent Encapsulating Peritoneal Sclerosis: Free Water Transport, Selected Effluent Proteins, or Both?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16300270" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Encapsulating peritoneal sclerosis--a clinician's approach to diagnosis and medical treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20584735" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25636412" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Interstitial Fibrosis Restricts Osmotic Water Transport in Encapsulating Peritoneal Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11098926" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17090782" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Simulations of osmotic ultrafiltration failure in CAPD using a serial three-pore membrane/fiber matrix model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30618825" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Ultrafiltration Failure Is a Reflection of Peritoneal Alterations in Patients Treated With Peritoneal Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18667742" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16300277" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16048272" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sclerosing peritonitis: a nosological entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14870877" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The natural course of peritoneal membrane biology during peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8105920" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Immunosuppression in sclerosing peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9261041" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11379862" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Sclerosing encapsulating peritonitis: a case successfully treated with immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16221244" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28360369" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Significant Decreasing Incidence of Encapsulating Peritoneal Sclerosis in the Dutch Population of Peritoneal Dialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14763031" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical experience with tamoxifen in peritoneal fibrosing syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16623426" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11216544" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Managing ultrafiltration failure by peritoneal resting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17704450" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effects of peritoneal resting on peritoneal fluid transport kinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15012689" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Sclerosing encapsulating peritonitis as a complication of long-term continuous ambulatory peritoneal dialysis in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16300271" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Successful surgical management of encapsulating peritoneal sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31744097" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
